Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies

Acta Diabetologica

Volumn 51, Issue 5, 2014, Pages 771-782

  Connelly, Kim A ^a   Advani, Andrew ^a   Advani, Suzanne L ^a   Zhang, Yuan ^b   Kim, Young M ^c   Shen, Vanessa ^a   Thai, Kerri ^a   Kelly, Darren J ^b   Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Reactive oxygen species; Thioredoxin; Thioredoxin interacting protein (TxnIP)

Indexed keywords

GLUCOSE; ISOPHANE INSULIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; ANTIOXIDANT; CARRIER PROTEIN; TXN PROTEIN, HUMAN; TXN1 PROTEIN, RAT; TXNIP PROTEIN, HUMAN; TXNIP PROTEIN, RAT;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATIONAL STUDY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; EXPERIMENTAL STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART WEIGHT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; METABOLIC FLUX ANALYSIS; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; METABOLISM;

ANIMALS; ANTIOXIDANTS; CARRIER PROTEINS; DIABETES MELLITUS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MYOCARDIUM; RATS; REACTIVE OXYGEN SPECIES; THIOREDOXINS;

EID: 84919494180     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0608-9     Document Type: Article

References (44)

1. Alter DA, Khaykin Y, Austin PC et al (2003) Processes and outcomes of care for diabetic acute myocardial infarction patients in Ontario: do physicians undertreat? Diabetes Care 26:1427–1434. doi:10.2337/diacare.26.5.1427
2. Uchmanowicz I, Loboz-Grudzien K, Jankowska-Polanska B, Sokalski L (2011) Influence of diabetes on health-related quality of life results in patients with acute coronary syndrome treated with coronary angioplasty. Acta Diabetol 50:217–225. doi:10.1007/s00592-011-0280-2
3. Donahoe SM, Stewart GC, McCabe CH et al (2007) Diabetes and mortality following acute coronary syndromes. JAMA 298:765–775. doi:10.1001/jama.298.7.765
4. Woodfield SL, Lundergan CF, Reiner JS et al (1996) Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. JAC 28:1661–1669. doi:10.1016/S0735-1097(96)00397-X
5. Gao F, Zhou YJ, Shen H et al (2012) Meta-analysis of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with diabetes and left main and/or multivessel coronary artery disease. Acta Diabetol 50:765–773. doi:10.1007/s00592-012-0411-4
6. Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384. doi:10.1056/NEJMoa1211585
7. Tarquini R, Lazzeri C, Pala L et al (2010) The diabetic cardiomyopathy. Acta Diabetol 48:173–181. doi:10.1007/s00592-010-0180-x
8. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820. doi:10.1038/414813a
9. Berlett BS (1997) Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272:20313–20316. doi:10.1074/jbc.272.33.20313
10. Yamawaki H, Berk BC (2005) Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr Opin Nephrol Hypertens 14:149
11. Emiroglu MY, Esen ÖB, Bulut M et al (2010) GGT levels in type II diabetic patients with acute coronary syndrome (does diabetes have any effect on GGT levels in acute coronary syndrome?). Acta Diabetol 50:21–25. doi:10.1007/s00592-010-0208-2
12. Chen K-S, DeLuca HF (1994) Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta (BBA)-Gene Struct Expr 1219:26–32. doi:10.1016/0167-4781(94)90242-9
13. Xiang G, Seki T, Schuster MD et al (2005) Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem 280:39394–39402. doi:10.1074/jbc.M502966200
14. Cheng DW, Jiang Y, Shalev A et al (2006) An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells. Arch Physiol Biochem 112:189–218. doi:10.1080/13813450601093518
15. Hirota T, Okano T, Kokame K et al (2002) Glucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured Rat-1 fibroblasts. J Biol Chem 277:44244–44251. doi:10.1074/jbc.M206233200
16. Kobayashi T, Uehara S, Ikeda T et al (2003) Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells. Kidney Int 64:1632–1642. doi:10.1046/j.1523-1755.2003.00263.x
17. Qi W, X Chen, Gilbert RE et al (2007) High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-β1. Am J Pathol 171:744–754. doi:10.2353/ajpath.2007.060813
18. Schulze PC, Yoshioka J, Takahashi T et al (2004) Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279:30369–30374. doi:10.1074/jbc.M400549200
19. Advani A, Gilbert RE, Thai K et al (2009) Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol 20:730–741. doi:10.1681/ASN.2008020142
20. Advani A, Kelly DJ, Cox AJ et al (2009) The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 54:261–269. doi:10.1161/HYPERTENSIONAHA.109.128645
21. Connelly KA, Advani A, Kim S et al (2011) The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. J Hypertens 29:1175–1184. doi:10.1097/HJH.0b013e3283462674
22. Holmgren A, Björnstedt M (1995) Thioredoxin and thioredoxin reductase. Meth Enzymol 252:199–208
23. Connelly KA, Kelly DJ, Zhang Y et al (2007) Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 76:280–291. doi:10.1016/j.cardiores.2007.06.022
24. Kuliszewski M, Kabir G, Fujii H et al (2011) 724 Characterisation of a novel rodent model of diabetes induced heart failure with preserved ejection fraction—the Goto Kakizaki rat. Can J Cardiol 27:S328. doi:10.1016/j.cjca.2011.07.598
25. Vahtola E, Louhelainen M, Merasto S et al (2008) Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto–Kakizaki rat. J Hypertens 26:334–344. doi:10.1097/HJH.0b013e3282f293c8
26. Connelly KA, Prior DL, Kelly DJ et al (2006) Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 290:H1699–H1705. doi:10.1152/ajpheart.00577.2005
27. Georgakopoulos D, Mitzner WA, Chen CH et al (1998) In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 274:H1416–H1422
28. Pacher P, Nagayama T, Mukhopadhyay P et al (2008) Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3:1422–1434. doi:10.1038/nprot.2008.138
29. Yang B, Larson DF, Beischel J et al (2001) Validation of conductance catheter system for quantification of murine pressure-volume loops. J Invest Surg 14:341–355. doi:10.1080/089419301753435710
30. Kelly DJ, Zhang Y, Hepper C et al (2003) Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52:512–518
31. Kai H, Muraishi A, Sugiu Y et al (1998) Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 83:594–601
32. Brownlee M (2005) The pathobiology of diabetic complications a unifying mechanism. Diabetes 54:1615–1625
33. Berndt C, Lillig CH, Holmgren A (2006) Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 292:H1227–H1236. doi:10.1152/ajpheart.01162.2006
34. Nishiyama A, Matsui M, Iwata S et al (1999) Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274:21645–21650
35. Junn E, Han SH, Im JY et al (2000) Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164:6287–6295
36. Chen J, Cha-Molstad H, Szabo A, Shalev A (2009) Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab 296:E1133–E1139. doi:10.1152/ajpendo.90944.2008
37. Turoczi T, Chang VW-H, Engelman RM et al (2003) Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol 35:695–704
38. Tanito M, Masutani H, Nakamura H et al (2002) Cytoprotective effect of thioredoxin against retinal photic injury in mice. Invest Ophthalmol Vis Sci 43:1162–1167
39. Minn AH, Hafele C, Shalev A (2005) Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146:2397–2405. doi:10.1210/en.2004-1378
40. Hui STY, Andres AM, Miller AK et al (2008) Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci USA 105:3921–3926. doi:10.1073/pnas.0800293105
41. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213–3223. doi:10.1161/CIRCULATIONAHA.106.679597
42. Yoshioka J, Chutkow WA, Lee S et al (2012) Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest 122:267–279. doi:10.1172/JCI44927DS1
43. Li X, Rong Y, Zhang M et al (2009) Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun 381:660–665. doi:10.1016/j.bbrc.2009.02.132
44. Ma L, Robinson LN, Towle HC (2006) ChREBP*Mlx Is the principal mediator of glucose-induced gene expression in the liver. J Biol Chem 281:28721–28730. doi:10.1074/jbc.M601576200